$1.75
0.00%
NYSE, Fri, Sep 27 2024
ISIN
KYG393421030
Symbol
CO

Global Cord Blood Corporation Stock price

$1.75
+0.55 45.83% 1M
+0.40 29.63% 6M
+0.53 43.44% YTD
+0.51 41.13% 1Y
-2.84 61.87% 3Y
-3.01 63.24% 5Y
-3.18 64.50% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.00 0.00%
ISIN
KYG393421030
Symbol
CO
Sector

Key metrics

Market capitalization $234.35m
Short interest 2.08%

Is Global Cord Blood Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Global Cord Blood Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Global Cord Blood Corporation:

1x Sell
100%

Analyst Opinions

1 Analyst has issued a forecast Global Cord Blood Corporation:

Sell
100%

Financial data from Global Cord Blood Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Mar '22
+/-
%
194 194
13% 13%
100%
- Direct Costs 31 31
7% 7%
16%
163 163
14% 14%
84%
- Selling and Administrative Expenses 57 57
12% 12%
29%
- Research and Development Expense 3.17 3.17
2% 2%
2%
103 103
17% 17%
53%
- Depreciation and Amortization 7.80 7.80
2% 2%
4%
EBIT (Operating Income) EBIT 95 95
18% 18%
49%
Net Profit 78 78
4% 4%
40%

In millions USD.

Don't miss a Thing! We will send you all news about Global Cord Blood Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Global Cord Blood Corporation Stock News

Neutral
PRNewsWire
3 months ago
NEW YORK , June 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court ...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation (“Global Cord” or the “Company”) (NYSE: CO, OTC: CORBF) and reminds investors of the June 24, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neutral
GlobeNewsWire
4 months ago
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation (“Global Cord” or the “Company”) (NYSE: CO, OTC: CORBF) and reminds investors of the June 24, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
More Global Cord Blood Corporation News

Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. It preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO Ting Zheng
Founded 2008
Website www.globalcordbloodcorporation.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today